Class: Prostaglandin Analogs
VA Class: OP109
Chemical Name: [1R-[1α(Z),2β(1E,3R*),3α,5α]]-7-[3,5-dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic acid 1-methylethyl ester
CAS Number: 157283-68-6
Brands: Travatan Z
Introduction
Ocular hypotensive agent; a synthetic analog of prostaglandin F2α (PGF2α).
Uses for Travoprost
Ocular Hypertension and Glaucoma
Reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.
Safety and efficacy not established for the treatment of angle-closure, inflammatory, or neovascular glaucoma.
Mean reductions in IOP may be up to 1.8 mm Hg greater in black patients than in other races; not known whether this difference is related to race or to heavily pigmented irides.
May be more effective than timolol 0.5% and equally or more effective than latanoprost 0.005% in reducing IOP in patients with open-angle glaucoma or ocular hypertension. Appears to be superior to timolol 0.5% or latanoprost 0.005% in reducing IOP in black patients.
Addition of travoprost 0.004% to timolol 0.5% therapy may result in additional reduction in IOP.
When selecting an initial ocular hypotensive agent, consider extent of the required IOP reduction, coexisting medical conditions, and drug characteristics (e.g., dosing frequency, adverse effects, cost). With single-agent regimens, the reduction in IOP is approximately 25–33% with topical prostaglandin analogs; 20–25% with topical β-adrenergic blocking agents, α-adrenergic agonists, or miotic (parasympathomimetic) agents; 20–30% with oral carbonic anhydrase inhibitors; 18% with topical rho kinase inhibitors; and 15–20% with topical carbonic anhydrase inhibitors.
A prostaglandin analog frequently is considered for initial therapy in the absence of other considerations (e.g., contraindications, cost considerations, intolerance, adverse effects, patient refusal) because of relatively greater activi...
